Pleural or pericardial metastasis: A significant factor affecting efficacy and adverse events in lung cancer patients treated with PD‐1/PD‐L1 inhibitors

BACKGROUND: Immunotherapy is a new paradigm for the treatment of non‐small‐cell lung cancer (NSCLC), and targeting the PD‐1 or PD‐L1 pathway is a promising therapeutic option. Although PD‐1/PD‐L1 inhibitors are more effective than standard chemotherapy in lung cancer, clinicians are afraid to active...

Descripción completa

Detalles Bibliográficos
Autores principales: Kang, Da Hyun, Chung, Chaeuk, Kim, Ju‐Ock, Jung, Sung Soo, Park, Hee Sun, Park, Dong Il, Jung, Sun Young, Park, Myoungrin, Lee, Jeong Eun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2018
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6209802/
https://www.ncbi.nlm.nih.gov/pubmed/30253080
http://dx.doi.org/10.1111/1759-7714.12877

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6209802/
https://www.ncbi.nlm.nih.gov/pubmed/30253080
http://dx.doi.org/10.1111/1759-7714.12877

Ejemplares similares